People · Operator
Named in public records as an officer, director or promoter · active 2008–2022 · Other, Software / Tech, Biotechnology, AI / ML, Other Technology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Trulieve Cannabis Corp. | — | Other | Growth/Late | $619.8M | $127.4M | 2018 |
| Keane Holdings Inc. | — | Other | Series C | $61.9M | $153.2M | 2014 |
| Venio Holding Corp | — | Other | Series B | $45.9M | $66.5M | 2008 |
| Aira Tech Corp. | — | Software / Tech | Series B | $32.2M | $522.6M | 2016 |
| Trulieve, Inc. | — | Other | Series B | $29.3M | $486.9M | 2018 |
| Kallyope, Inc. | — | Biotechnology | Series B | $28.1M | $1.1B | 2015 |
| Viz.Ai, Inc. | — | AI / ML | Series A | $7.3M | $172.5M | 2016 |
| Icopyright Inc | — | Other Technology | Seed | $2.6M | $89.3M | 2011 |
| Pain Therapeutics Inc | — | Pharmaceuticals | Seed | $1.1M | $42.1M | 2018 |
| Primal Therapies, Inc. | — | Biotechnology | Pre-Seed | $677K | $37.4M | 2016 |
| Paradigm Blockchain Holdings Inc | — | Crypto / Web3 | Pre-Seed | $250K | $3.9M | 2022 |
Michael O'Donnell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael O'Donnell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| George Hackney | 2 | 2 |
| Mohan Srinivasan | 2 | 2 |
| Kim Rivers | 2 | 2 |
| Benjamin Atkins | 2 | 2 |
| Richard May | 2 | 2 |
| John Harris | 1 | 20 |
| Adam Goulburn | 1 | 10 |
| Terry McGuire | 1 | 8 |
| Josh Wolfe | 1 | 8 |
| DROR BERMAN | 1 | 8 |
| Tim Kutzkey | 1 | 7 |
| Scott Minick | 1 | 7 |
| William Smith | 1 | 6 |
| Joshua Wolfe | 1 | 4 |
| William Rieflin | 1 | 4 |
| Saira Ramasastry | 1 | 4 |
| Thomas Shehab | 1 | 4 |
| Keith Pennell | 1 | 4 |
| Kenneth Clark | 1 | 3 |
| Brett Prager | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.